# Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers

> **NCT06715163** · NA · COMPLETED · sponsor: **AB Biotek** · enrollment: 43 (actual)

## Conditions studied

- Safety and Tolerability in Healthy Volunteers

## Interventions

- **DIETARY_SUPPLEMENT:** Dose 1 (42mg) of DAO
- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** Dose 2 (84mg) of DAO
- **DIETARY_SUPPLEMENT:** Dose 3 (210mg) of DAO

## Key facts

- **NCT ID:** NCT06715163
- **Lead sponsor:** AB Biotek
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-08
- **Primary completion:** 2024-07-29
- **Final completion:** 2024-07-29
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715163, "Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06715163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*